Chlorproguanil hydrochloride-dapsone-artesunate
Jump to navigation
Jump to search
Chlorproguanil-dapsone-artesunate (abbreviated CDA) is a new antimalarial treatment that entered Phase III clinical trials in 2006. It is being compared against artemether-lumefantrine (Coartem®) and against chlorproguanil-dapsone Lapdap™. This drug is being developed in collaboration between GlaxoSmithKline, UNICEF, the World Bank, Medicines for Malaria Venture and the WHO Special Programme for Research and Training in Tropical Diseases (WHO/TDR), the Liverpool School of Tropical Medicine, and the London School of Hygiene and Tropical Medicine.[1]
References
- ↑ Das P (2006). "Promising anti-malarial enters phase II studies". Lancet Infect Dis. 6 (9): 551.
External links
 | This antimicrobial-related article is a stub. You can help Wikipedia by expanding it. |